An Experience of Cyberknife Treatment in Patients with Advanced Pancreaticobilliary Malignancy.
10.4166/kjg.2011.58.5.264
- Author:
Yun Ho JUNG
1
;
Hyun Sook CHOI
;
Young Koog CHEON
;
Jong Ho MOON
;
Young Deok CHO
;
Ah Ram CHANG
;
Jong Ho WON
Author Information
1. Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea. ydcho@schmc.ac.kr
- Publication Type:Original Article ; English Abstract
- Keywords:
Pancreaticobiliary malignancies;
Cyberknife SBRT
- MeSH:
Adult;
Aged;
CA-19-9 Antigen/analysis;
Common Bile Duct Neoplasms/complications/pathology/*surgery;
Female;
Gallbladder Neoplasms/complications/pathology/*surgery;
Gastrointestinal Hemorrhage/etiology;
Humans;
Male;
Middle Aged;
Pancreatic Neoplasms/complications/pathology/*surgery;
Radiosurgery;
Retrospective Studies;
Tomography, X-Ray Computed
- From:The Korean Journal of Gastroenterology
2011;58(5):264-269
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: CyberKnife(TM) stereotactic body radiotherapy (SBRT) has been thought as a promising treatment modality for inoperable or recurred pancreaticobiliary malignancies. But, clinical course of CyberKnife(TM) treatment have not been established yet, so we report the experience of CyberKnife(TM) treatment in 19 patients with recurred or advanced pancreaticobilliary malignancies. METHODS: Between July 2008 and May 2009, 19 patients (gallbladder cancer 4, common bile duct cancer 5, and pancreatic cancer 10) with recurred (12) and advanced pancreaticobiliary cancer (7) underwent CyberKnife(TM) treatment in Soonchunhyang University Hospital. Tumor size was evaluated at 1, 3, 6, 8 and every 3 months after SBRT. RESULTS: The mean age was 60.2 years, and the mean size of target lesions was 28.1+/-1.30 mm. After CyberKnife(TM) treatment, the average size of target lesions was decreased; 2.53+/-4.18 mm from months 0-1 in 19 patients, 2.47+/-4.7 mm from months 1-3 in 15 patients, 0.08+/-5.11 mm from months 3-6 in 12 patients. However, the average size of target lesions was increased 3.67+/-8.98 mm from months 6-8 in 6 patients. There were 2 cases of massive duodenal ulcer bleeding after CyberKnife(TM) treatment, one of them expired due to ulcer bleeding. Also, other minor complications appeared such as 1 case of abdominal pain and 1 case of diarrhea. CONCLUSIONS: CyberKnife(TM) treatment seems to be effective in local control of pancreaticobiliary cancer, but we experienced serious complications. Further prospective studies will be needed for the proper evaluation of role of Cyberknife(TM) treatment in patients with advanced pancreaticobiliary malignancies.
